Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 5
2020 4
2021 3
2022 3
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic significance of circulating tumor cells and tumor related transcripts in small cell lung cancer: A step further to clinical implementation.
Welsch E, Holzer B, Schuster E, Fabikan H, Weinlinger C, Hauptmann-Repitz E, Illini O, Hochmair MJ, Fischer MB, Weiss E, Zeillinger R, Obermayr E. Welsch E, et al. Among authors: weinlinger c. Int J Cancer. 2024 Jun 15;154(12):2189-2199. doi: 10.1002/ijc.34886. Epub 2024 Feb 14. Int J Cancer. 2024. PMID: 38353516
Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis.
Hochmair MJ, Fabikan H, Illini O, Weinlinger C, Setinek U, Krenbek D, Prosch H, Rauter M, Schumacher M, Wöll E, Wass R, Brehm E, Absenger G, Bundalo T, Errhalt P, Urban M, Valipour A. Hochmair MJ, et al. Among authors: weinlinger c. Pharmaceuticals (Basel). 2020 Nov 7;13(11):371. doi: 10.3390/ph13110371. Pharmaceuticals (Basel). 2020. PMID: 33171712 Free PMC article.
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.
Illini O, Fabikan H, Swalduz A, Vikström A, Krenbek D, Schumacher M, Dudnik E, Studnicka M, Öhman R, Wurm R, Wannesson L, Peled N, Kian W, Bar J, Daher S, Addeo A, Rotem O, Pall G, Zer A, Saad A, Cufer T, Sorotsky HG, Hashemi SMS, Mohorcic K, Stoff R, Rovitsky Y, Keren-Rosenberg S, Winder T, Weinlinger C, Valipour A, Hochmair MJ. Illini O, et al. Among authors: weinlinger c. Ther Adv Med Oncol. 2022 Jun 13;14:17588359221103206. doi: 10.1177/17588359221103206. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35720834 Free PMC article.
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
Illini O, Hochmair MJ, Fabikan H, Weinlinger C, Tufman A, Swalduz A, Lamberg K, Hashemi SMS, Huemer F, Vikström A, Wermke M, Absenger G, Addeo A, Banerji S, Calles A, Clarke S, Di Maio M, Durand A, Duruisseaux M, Itchins M, Kääränien OS, Krenn F, Laack E, de Langen AJ, Mohorcic K, Pall G, Passaro A, Prager G, Rittmeyer A, Rothenstein J, Schumacher M, Wöll E, Valipour A. Illini O, et al. Among authors: weinlinger c. Ther Adv Med Oncol. 2021 Jun 11;13:17588359211019675. doi: 10.1177/17588359211019675. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34178121 Free PMC article.
Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion-Positive Metastatic Lung Cancer.
Hochmair MJ, Setinek U, Krenbek D, Fazekas A, Illini O, Weinlinger C, Draxler H, Marcher M, Valipour A, Müllauer L, Beer L. Hochmair MJ, et al. Among authors: weinlinger c. Clin Lung Cancer. 2020 Mar;21(2):e49-e53. doi: 10.1016/j.cllc.2019.11.010. Epub 2019 Nov 20. Clin Lung Cancer. 2020. PMID: 31879191 No abstract available.
16 results